PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

Natalizumab

As specified in the treatment arm

Trial Locations (5)

Research Site, Cefalù

Research Site, Gallarate

Research Site, Milan

Research Site, Padua

Research Site, Rome